BiotechTube

autologous cultured chondrocytes on porcine collagen membrane

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Articular Cartilage Defect

Conditions

Articular Cartilage Defect

Trial Timeline

Jul 1, 2008 → Mar 1, 2012

NCT ID
NCT00719576

About autologous cultured chondrocytes on porcine collagen membrane

autologous cultured chondrocytes on porcine collagen membrane is a phase 3 stage product being developed by Vericel for Articular Cartilage Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00719576. Target conditions include Articular Cartilage Defect.

What happened to similar drugs?

1 of 4 similar drugs in Articular Cartilage Defect were approved

Approved (1) Terminated (0) Active (3)
✅Carticel (autologous cultured chondrocyte) implantationVericelApproved
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AbataceptBristol Myers SquibbPhase 3
🔄Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)UCBPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06915233Phase 3Recruiting
NCT01251588Pre-clinicalCompleted
NCT00719576Phase 3Completed

Competing Products

6 competing products in Articular Cartilage Defect

See all competitors
ProductCompanyStageHype Score
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AbataceptBristol Myers SquibbPhase 3
40
Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)UCBPhase 3
40
autologous cultured chondrocytes on porcine collagen membraneVericelPre-clinical
20
Carticel (autologous cultured chondrocyte) implantationVericelPre-clinical
20
Carticel (autologous cultured chondrocyte) implantationVericelApproved
37